Abstract
When a new medical product is released to the market, a continuous pharmacovigilance process is initiated to guarantee patient safety by collecting and analyzing adverse drug reaction (ADR) reports. These ADRs are noxious and unintended responses to a medicine and are collected and analyzed in databases like EudraVigilance to determine safety profiles of the products and signal detection. The spontaneous reporting of suspected ADR could be performed by both health care workers and patients/consumers. However, the under-reporting is well known. Different initiatives have been developed to encourage reporting by health professionals, however, further work is required to support patients in taking a more active role in reporting adverse drug reactions. In this context, we will conduct a Scoping Review of the literature to inquire about what is known about actions or strategies to improve pharmacovigilance engagement by patients. We will conduct searches in MEDLINE/PubMed, Scielo, Latindex, DOAJ, CINAHL, LILACS, IAM, IMEMR, IMSEAR, WPRO, and Cochrane Library databases. Two reviewers will screen all identified records for relevance. Conflicts between reviewers will be solved by consensus. We will chart the data using data-charting forms. Findings will be reported according to PRISMA for Scoping Reviews (PRISMA-ScR). No quality assessment will be performed.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript
